ArticleOncology letters2017
Angiotensin II receptor blockers induce autophagy in prostate cancer cells.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Pooled it
- Effects of Inhibitors of the Activity of the Circulating Renin-Angiotensin System on the Growth and Proliferation of Endometrial Cancer Cells.International journal of molecular sciences · 2025Article
- Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence.European heart journal · 2024Review
- The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies.Cancer cell international · 2023Review
- Endothelial Autophagy Dysregulation in Diabetes.Cells · 2023Review
- Angiotensin Receptor Blocker Associated with a Decreased Risk of Lung Cancer: An Updated Meta-Analysis.Journal of personalized medicine · 2023Article
- Geroscience-guided repurposing of FDA-approved drugs to target aging: A proposed process and prioritization.Aging cell · 2022Review
- Angiotensin II and Angiotensin Receptors 1 and 2-Multifunctional System in Cells Biology, What Do We Know?Cells · 2021Review
- The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer.Frontiers in oncology · 2021Review
- Mechanobiology of Autophagy: The Unexplored Side of Cancer.Frontiers in oncology · 2021Review
- Angiotensin System Inhibitors May Improve Outcomes of Patients With Castration-Resistant Prostate Cancer During Abiraterone Acetate Treatment-A Cardio-Oncology Study.Frontiers in oncology · 2021Article
- Rapamycin Promotes ROS-Mediated Cell DeathFrontiers in oncology · 2021Article
- The Effect of Local Renin Angiotensin System in the Common Types of Cancer.Frontiers in endocrinology · 2021Review
- Autophagy in metabolic syndrome: breaking the wheel by targeting the renin-angiotensin system.Cell death & disease · 2020Review
- TLR7 Stimulation With Imiquimod Induces Selective Autophagy and ControlsFrontiers in microbiology · 2020Article
- Inhibiting eukaryotic ribosome biogenesis.BMC biology · 2019Article
- Inflammation and NF-κB Signaling in Prostate Cancer: Mechanisms and Clinical Implications.Cells · 2018Review
- Article
- Therapeutic potential of valsartan in overcoming chemoresistance in human glioblastoma.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiotensin II receptor blockers (ARBs) are anti-hypertensive drugs that competitively inhibit the binding of angiotensin II to its receptor, resulting in blood vessel dilation and the reduction of blood pressure. These antagonists are also known as sartans, and are a group of pharmaceuticals that possess tetrazole or imidazole groups. In the present study, the anticancer and antimetastatic effects of the ARBs fimasartan, losartan, eprosartan and valsartan on the human prostate cancer PC-3, DU-145 and LNCap-LN3 cell lines were investigated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.